Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8378595 | 0.91 | LMNA (0.60) | LMNACYP2C19HIF1A | |
| SCHEMBL8978151 | 0.90 | LMNA (0.71) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL8375497 | 0.87 | LMNA (0.56) | LMNACYP2C19HIF1A | |
| SCHEMBL8373498 | 0.86 | LMNA (0.66) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL14310826 | 0.86 | LMNA (0.83) | LMNASMN1; SMN2CYP2C19HIF1A | |
| SCHEMBL10875551 | 0.84 | LMNA (0.63) | LMNASMN1; SMN2CYP2C19HIF1A | |
| Ioxitalamic Acid SCHEMBL29815239 | 0.83 | LMNA (0.57) | LMNASMN1; SMN2CYP2C19HIF1AGAA | |
| Ioxitalamic Acid SCHEMBL455411 | 0.83 | LMNA (0.57) | LMNASMN1; SMN2CYP2C19HIF1AGAA | |
| SCHEMBL622239 | 0.83 | LMNA (0.54) | LMNASMN1; SMN2CYP2C19HIF1AGAA | |
| SCHEMBL2764077 | 0.82 | LMNA (0.50) | LMNACYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8535642-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2013-09-17 | — | — | US | disclosed |
| US-20120039815-A9 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-02-16 | — | — | US | disclosed |
| US-20110052504-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-03-03 | — | — | US | disclosed |
| US-20110008263-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-01-13 | — | — | US | disclosed |
| EP-2245003-A2 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-11-03 | — | — | EP | disclosed |
| EP-2245004-A2 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009106552-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106551-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039815-A9 | CONTRAST AGENTS | C5, TXN, CBR3 | LMNA 1863/4885SMN1; SMN2 3850/4885CYP2C19 3568/4885 |
| US-20110052504-A1 | CONTRAST AGENTS | C5, TXN, CBR3 | LMNA 1863/4885SMN1; SMN2 3850/4885CYP2C19 3568/4885 |
| US-20110008263-A1 | CONTRAST AGENTS | C5, C1R, C3AR1 | LMNA 1002/4885SMN1; SMN2 4579/4885CYP2C19 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.